Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice.

Authors:
Prof. Hesham El-Beshbishy, PhD
Prof. Hesham El-Beshbishy, PhD
Prof. Medical Biochemistry and Molecular Biology
Professor
Medical Biochemistry and Molecular Biology
Madina, Madina | SA

Cancer Chemother Pharmacol 2014 Sep 23;74(3):559-69. Epub 2014 Jul 23.

Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, P.O. Box 30001, El-Madinah, El-Munaworah, Saudi Arabia,

Purpose: This study was undertaken to assess the possible modulatory effects and mechanisms of meloxicam, a cyclooxygenase-2 inhibitor, on the antitumor activity and cardiotoxicity of doxorubicin in a mice model of mammary carcinoma.

Methods: Solid tumor mass was developed in female albino mice using Ehrlich carcinoma cells. Forty mice-bearing tumor were divided randomly into four groups for treatment: with saline, meloxicam 10 mg/kg, doxorubicin 5 mg/kg and meloxicam 1 h ahead of doxorubicin, twice weekly for 2 weeks. Tumor volume was followed up and cardiac protective utility was estimated via measuring heart and serum parameters.

Results: Meloxicam expressed a non-significant increase in doxorubicin antitumor activity. Conversely, meloxicam significantly (p < 0.01) mitigated doxorubicin-induced elevation of serum cardiac enzymes [creatine kinase, lactate dehydrogenase and troponin-I]; cardiac lipid peroxidations marker; cardiac active caspase-3 content; and cardiac prostaglandin E2 content. Meloxicam significantly abrogated doxorubicin-induced disturbance in heart histology and relative heart weight to body weight. Meloxicam normalized doxorubicin-induced suppression in heart antioxidant enzymes activities and gene expressions [superoxide dismutase, glutathione peroxidase (GSH-Px) and catalase], and heart GSH content. In addition, meloxicam ameliorated doxorubicin-induced disturbance in phase II metabolizing enzyme, cardiac quinone reductase (QR), at activity level and mRNA expression.

Conclusion: Meloxicam protects heart against doxorubicin toxicity without affecting its antitumor activity against solid mammary cancer model in mice. This protective effect is attributed to antioxidant effect, antiradical effect, antiinflammatory action, antiapoptotic effect and induction of QR enzyme.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2544-3DOI Listing
September 2014
14 Reads
2 Citations
2.770 Impact Factor

Publication Analysis

Top Keywords

antitumor activity
16
meloxicam
10
doxorubicin mice
8
modulatory effects
8
doxorubicin-induced disturbance
8
cardiac
6
heart
6
doxorubicin
6
activity
5
content meloxicam
4
meloxicam abrogated
4
prostaglandin content
4
abrogated doxorubicin-induced
4
content cardiac
4
caspase-3 content
4
cardiac active
4
active caspase-3
4
cardiac prostaglandin
4
marker cardiac
4
relative heart
4

References

(Supplied by CrossRef)

F Arcamone et al.
Biotechnol Bioeng 1969

DW Kufe et al.
2003

DA Gewirtz et al.
Biochem Pharmacol 1999

G Minotti et al.
Pharmacol Rev 2004

BK Sinha et al.
Cancer Res 1984

M Binaschi et al.
Curr Med Chem Anticancer Agents 2001

JR Muindi et al.
FEBS Lett 1984

PL Gutierrez et al.
Free Radic Biol Med 2000

AM Osman et al.
Cancer Cell Int 2013

S Adderley et al.
J Biol Chem 1999

Similar Publications